Hyperbaric Device and Methods for Producing Inactivated Vaccines and for Refolding/Solubilizing Recombinant Proteins
US-2016000896-A1 · Jan 7, 2016 · US
Expression of chimeric KSAC protein and method of producing soluble proteins by high pressure
US10364274B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10364274-B2 |
| Application number | US-201615017486-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 5, 2016 |
| Priority date | Aug 30, 2012 |
| Publication date | Jul 30, 2019 |
| Grant date | Jul 30, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention encompasses vaccines or compositions comprising the chimeric KSAC protein that possesses immunogenic and protective properties, and methods of use including administering to an animal the antigenic KSAC protein thereof to protect animals. The invention also encompasses methods for making and producing the soluble, disaggregated, refolded or active proteins from inclusion bodies produced from prokaryotes or eukaryotes.
First claim
Opening claim text (preview).
What we claim is: 1. A composition comprising (i) a refolded and solubilized fusion protein and (ii) dithiothreitol (DTT), wherein the fusion protein consists of leishmania antigens Kinetoplastid Membrane Protein 11 (KMP11), Sterol MethylTransferase (SMT), A2 and Cysteine Proteinase (CP), and wherein the fusion protein comprises the sequence as set forth in SEQ ID NO:2. 2. The composition of claim 1 , wherein the fusion protein was encoded by a polynucleotide having the sequence as set forth in SEQ ID NO: 1. 3. The composition of claim 1 , wherein the fusion protein was refolded under a pressure from about 1000 bar to about 5000 bar. 4. The composition of claim 3 , wherein the fusion protein was refolded under the pressure for at least 20 hours. 5. The composition of claim 1 , wherein the fusion protein was solubilized from Escherichia coli inclusion bodies. 6. The composition of claim 5 , wherein the E. coli inclusion bodies were prepared in a buffer comprising no or low urea. 7. The composition of claim 5 , wherein the E. coli inclusion bodies were prepared in a buffer comprising DTT. 8. The composition of claim 5 , wherein the E. coli inclusion bodies were treated under high pressure for about 20 hours to about 100 hours. 9. The composition of claim 8 , wherein the E. coli inclusion bodies were depressurized at a rate of about 83 bar/hr-125 bar/hr. 10. The composition of claim 1 , wherein the fusion protein was refolded under a high pressure that was increased in a stepwise process.
Assignees
Inventors
Classifications
from yeast · CPC title
Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis · CPC title
Antibacterial agents · CPC title
- C12Y304/22Primary
Cysteine endopeptidases (3.4.22) · CPC title
Sterol 24-C-methyltransferasee (2.1.1.41) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10364274B2 cover?
- The present invention encompasses vaccines or compositions comprising the chimeric KSAC protein that possesses immunogenic and protective properties, and methods of use including administering to an animal the antigenic KSAC protein thereof to protect animals. The invention also encompasses methods for making and producing the soluble, disaggregated, refolded or active proteins from inclusion b…
- Who is the assignee on this patent?
- Boehringer Ingelheim Animal Health Usa Inc, Boehringer Ingelheim Animal Heatlh Usa Inc
- What technology area does this patent fall under?
- Primary CPC classification C12Y304/22. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).